Apratoxin A vs Mambalgin-1
Head-to-head comparison of Apratoxin A (Apratoxin A) and Mambalgin-1 (Mambalgin-1 from Dendroaspis polylepis venom) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Apratoxin A | Mambalgin-1 |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Apratoxin A | Mambalgin-1 from Dendroaspis polylepis venom |
| Molecular Weight | N/A | 6,300 Da |
| Half-Life | N/A | Minutes to hours |
| Amino Acids | N/A | 57 |
| Typical Dose | N/A in humans; nanomolar in vitro | 0.1-1 nmol intrathecal|10-100 nM in vitro|single-dose rodent studies |
| Route | Intraperitoneal / Intravenous (preclinical) | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 140 | 55 |
| Research Status | Pre-clinical | Pre-clinical |
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
Mambalgin-1 Benefits
- ✓ASIC channel inhibition
- ✓non-opioid analgesia research
- ✓sensory-neuron physiology
- ✓lead optimization for pain therapeutics
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
Mambalgin-1 Dosing
Intrathecal pain-behavior studies|ASIC1a/ASIC1b electrophysiology|Acute dosing in rodents
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Mambalgin-1 Side Effects
- ⚠Hypoactivity at high dose
- ⚠off-target ASIC blockade
- ⚠local irritation
Research Overview
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Mambalgin-1
Pre-clinical work shows mambalgin-1 can reduce pain behaviors by modulating proton-gated ion channels in peripheral and central pathways. It has become an important template for developing ASIC-targeted analgesics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.